Hormone replacement therapy in prostate cancer is androgen deprivation.
This deprivation causes side effects that are well known. The most frequent complications are hot flashes, erectile dysfunction and libido disorders. These complications have a strong impact on the quality of life of the patient. The other side effects, namely metabolic syndrome and osteopenia, are less frequent, but have a worse prognosis due to their significant impact on patients' survival. The metabolic syndrome results in dyslipidaemia and insulin resistance. Patients under hormone therapy must have an initial evaluation and a subsequent close monitoring. Screening for these side effects and their specific management must be essential during the monitoring of long-term hormone therapy.
Written by:
Bonniol R, Timsit MO. Are you the author?
Service d'urologie HEGP-Necker, AP-HP, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France.
Reference: Prog Urol. 2012 Nov;22(14):881-5.
doi: 10.1016/j.purol.2012.04.017
PubMed Abstract
PMID: 23101960
Article in French.
UroToday.com Prostate Cancer Section
